siRNA against CD40 delivered via a fungal recognition receptor ameliorates murine acute graft‐versus‐host disease

Abstract

Acute graft-versus-host disease (aGvHD) remains a major threat to a successful outcome after allogeneic hematopoietic stem cell transplantation (HSCT). Although antibody-based targeting of the CD40/CD40 ligand costimulatory pathway can prevent aGvHD, side effects hampered their clinical application, prompting a need for other ways to interfere with this important dendritic T-cell costimulatory pathway.Here, we used small interfering RNA (siRNA) complexed with β-glucan allowing the binding and uptake of the siRNA/β-glucan complex (siCD40/schizophyllan [SPG]; chemical modifications called NJA-312, NJA-302, and NJA-515) into Dectin1+ cells, which recognize this pathogen-associated molecular pattern receptor. aGvHD was induced by the transplantation of splenocytes and bone marrow cells from C57BL/6J into CBF1 mice. Splenic dendritic cells retained Dectin1 expression after HSCT but showed lower expression after irradiation. The administration of siCD40/SPG, NJA-312, and NJA-302 ameliorated aGvHD-mediated lethality and tissue damage of spleen and liver, but not skin. Multiple NJA-312high injections prevented aGvHD but resulted in early weight loss in allogeneic HSCT mice. In addition, NJA-312 treatment caused delayed initial donor T and B-cell recovery but resulted in stable chimerism in surviving mice. Mechanistically, NJA-312 reduced organ damage by suppressing CCR2+, F4/80+, and IL17A-expressing cell accumulation in spleen, liver, and thymus but not the skin of mice with aGvHD. Our work demonstrates that siRNA targeting of CD40 delivered via the PAMP-recognizing lectin Dectin1 changes the immunological niche, suppresses organ-specific murine aGvHD, and induces immune tolerance after organ transplantation. Our work charts future directions for therapeutic interventions to modulate tissue-specific immune reactions using Pathogen-associated molecular pattern (PAMP) molecules like 1,3-β-glucan for cell delivery of siRNA.

Recent Progress of Small Interfering RNA Delivery on the Market and Clinical Stage

“…Oligonucleotides form complexes with SPG molecules that recognize and bind to dectin-1, which is highly expressed on immune cells. 136 NJA-312 extended the lifespan of mice, demonstrating the effectiveness of SPG. 136 Due to advancements in delivery systems, siRNA therapies have shown promising potential for commercialization in the treatment of hepatic diseases.…”

“…136 NJA-312 extended the lifespan of mice, demonstrating the effectiveness of SPG. 136 Due to advancements in delivery systems, siRNA therapies have shown promising potential for commercialization in the treatment of hepatic diseases. Furthermore, researchers are actively exploring various strategies to develop long-acting siRNAs.…”

“…NapaJen Pharma has a schizophyllan glucan (SPG) delivery platform. Oligonucleotides form complexes with SPG molecules that recognize and bind to dectin-1, which is highly expressed on immune cells . NJA-312 extended the lifespan of mice, demonstrating the effectiveness of SPG …”